<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000677</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 125</org_study_id>
    <secondary_id>C89-258</secondary_id>
    <nct_id>NCT00000677</nct_id>
  </id_info>
  <brief_title>SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy</brief_title>
  <official_title>SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To assess the safety and effectiveness of SCH 39304 as primary treatment of acute&#xD;
      cryptococcal meningitis in HIV-infected patients. Safety and effectiveness of maintenance&#xD;
      therapy following successful treatment of acute disease are also evaluated.&#xD;
&#xD;
      Cryptococcal meningitis is a significant cause of illness and death in HIV-infected patients.&#xD;
      Intravenous amphotericin B is effective for acute disease but relapse occurs in the majority&#xD;
      of patients. Maintenance therapy is recommended but must be balanced against the multiple&#xD;
      toxicities of the drugs used and the problems associated with the weekly administration of&#xD;
      intravenous therapy. Treatments that are equally or more effective and less toxic than&#xD;
      traditional methods are needed, especially oral therapy. SCH 39304 is an orally active&#xD;
      antifungal drug that in animal studies is active against a wide range of systemic fungal&#xD;
      infections including infections due to Cryptococcus. Features of SCH 39304 suggest that it&#xD;
      might be of value in the treatment of cryptococcal meningitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cryptococcal meningitis is a significant cause of illness and death in HIV-infected patients.&#xD;
      Intravenous amphotericin B is effective for acute disease but relapse occurs in the majority&#xD;
      of patients. Maintenance therapy is recommended but must be balanced against the multiple&#xD;
      toxicities of the drugs used and the problems associated with the weekly administration of&#xD;
      intravenous therapy. Treatments that are equally or more effective and less toxic than&#xD;
      traditional methods are needed, especially oral therapy. SCH 39304 is an orally active&#xD;
      antifungal drug that in animal studies is active against a wide range of systemic fungal&#xD;
      infections including infections due to Cryptococcus. Features of SCH 39304 suggest that it&#xD;
      might be of value in the treatment of cryptococcal meningitis.&#xD;
&#xD;
      HIV-infected patients with a diagnosis of acute cryptococcal meningitis, previously untreated&#xD;
      or relapsed following a successfully treated acute episode, are enrolled in the study. SCH&#xD;
      39304 is administered orally once daily for 3 days followed by a lower dose once daily for 12&#xD;
      weeks. Patients who respond to primary therapy are randomized to receive SCH 39304&#xD;
      maintenance therapy at a higher dose once weekly or at the lower dose once daily for up to 12&#xD;
      months under this protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Meningitis, Cryptococcal</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 39304</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Currently approved antiviral therapy.&#xD;
&#xD;
          -  Maintenance therapy for cytomegalovirus retinitis or toxoplasmosis.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Dilantin or barbiturates if investigator agrees to rigorously monitor anticonvulsant&#xD;
             drug levels.&#xD;
&#xD;
          -  Coumarin-type anticoagulants if investigator agrees to rigorously monitor prothrombin&#xD;
             time.&#xD;
&#xD;
          -  Prophylactic treatment for Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Local radiotherapy for mucocutaneous Kaposi's sarcoma.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Amphotericin B, up to 1 mg/kg, during the previous 7 days.&#xD;
&#xD;
        Patients must be HIV positive by 2 methodologies and have either primary cryptococcal&#xD;
        meningitis with no prior anti-cryptococcal therapy or relapsed disease after prior therapy.&#xD;
&#xD;
          -  Prior therapy for cryptococcal meningitis is limited to approved drugs.&#xD;
&#xD;
          -  Written informed consent either from patient or patient's parent or legal guardian is&#xD;
             required.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  History of hypersensitivity to imidazole or azole compounds.&#xD;
&#xD;
          -  Central nervous system disease.&#xD;
&#xD;
          -  Acute opportunistic infection.&#xD;
&#xD;
          -  Underlying conditions that in the opinion of the investigator could preclude&#xD;
             assessment of response.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Systemic antifungal drugs other than study drug.&#xD;
&#xD;
          -  Any investigational drug other than treatment IND drugs.&#xD;
&#xD;
          -  Oral hypoglycemic agents.&#xD;
&#xD;
          -  Oral contraceptives.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Unable to take oral medications.&#xD;
&#xD;
          -  Concurrent central nervous system disease which in opinion of investigator would&#xD;
             interfere with assessment of response.&#xD;
&#xD;
          -  Concurrent acute opportunistic infection requiring therapy (patients who develop an&#xD;
             acute opportunistic infection after initiation of study medication may remain on study&#xD;
             medication).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 7 days of study entry:&#xD;
&#xD;
          -  Amphotericin B, &gt; 1 mg/kg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WG Powderly</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Veterans Administration Med Ctr</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Robert Larsen</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California / San Diego Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921036325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>462025250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis Regional Hosp / St Louis Regional Med Ctr</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Veterans Administration / Mount Sinai Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erie County Med Ctr</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holmes Hosp / Univ of Cincinnati Med Ctr</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp of Cleveland / Case Western Reserve Univ</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univ Med Ctr</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buckley Braffman Stern Med Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Veterans Administration Med Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Health Science Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audie L Murphy Veterans Administration Hosp</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond AIDS Consortium</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee BL, Padula AM, Tauber MG, Chambers HF, Sande MA. Oral SCH 39304 as primary, salvage, and maintenance therapy for cryptococcal meningitis in AIDS. J Acquir Immune Defic Syndr (1988). 1992;5(6):600-4.</citation>
    <PMID>1588494</PMID>
  </reference>
  <verification_date>December 1994</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Sch 39304</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Cryptococcosis</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sch 39304</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

